BACKGROUND: Major depressive disorder (MDD) is a highly prevalent and burdening mental illness. Approximately 30% of the major depressive episodes (MDE) are classified as therapy-refractory. Further knowledge of the pathophysiological mechanisms underlying MDD and predictive biomarkers are needed to improve treatment options. METHODS: Serum lipid levels were compared between patients with a current MDE (n = 130) or remitted MDD (n = 39) and healthy control subjects (n = 61) and associated with the severity (17-item Hamilton Depression Rating Scale [HAMD] scores) and the prospective course of depression (direct follow-up of at median 20 days post-inclusion). RESULTS: We found higher levels of LDL cholesterol (152.5 vs. 134.0 mg/dl, U = 3021, P = 0.008) and LDL/HDL ratio (2.82 vs. 2.21, U = 2912, P = 0.003) in patients with a current MDE than in healthy control subjects. In patients with a current MDE, higher HAMD scores correlated also with higher values of triglycerides (ρ = 0.213, P = 0.015), total cholesterol (ρ = 0.199, P = 0.023), LDL cholesterol (ρ = 0.224, P = 0.010), and LDL/HDL ratio (ρ = 0.196, P = 0.026). Moreover, higher total cholesterol (ρ = -0.233, P = 0.010), LDL cholesterol (ρ = -0.235, P = 0.010), and LDL/HDL ratio (ρ = -0.199, P = 0.029) were associated with a stronger decline in HAMD score between study inclusion and direct follow-up. LIMITATIONS: We employed an associational study design, performed only a short-term follow-up, and excluded suicidal study subjects. CONCLUSIONS: Serum lipid levels are associated with depression per se, the depression severity, and the prospective 3-week course. These observations build the basis for future investigations on individualized lipid metabolism-related treatment strategies in depressed patients.
BACKGROUND: Major depressive disorder (MDD) is a highly prevalent and burdening mental illness. Approximately 30% of the major depressive episodes (MDE) are classified as therapy-refractory. Further knowledge of the pathophysiological mechanisms underlying MDD and predictive biomarkers are needed to improve treatment options. METHODS: Serum lipid levels were compared between patients with a current MDE (n = 130) or remitted MDD (n = 39) and healthy control subjects (n = 61) and associated with the severity (17-item Hamilton Depression Rating Scale [HAMD] scores) and the prospective course of depression (direct follow-up of at median 20 days post-inclusion). RESULTS: We found higher levels of LDL cholesterol (152.5 vs. 134.0 mg/dl, U = 3021, P = 0.008) and LDL/HDL ratio (2.82 vs. 2.21, U = 2912, P = 0.003) in patients with a current MDE than in healthy control subjects. In patients with a current MDE, higher HAMD scores correlated also with higher values of triglycerides (ρ = 0.213, P = 0.015), total cholesterol (ρ = 0.199, P = 0.023), LDL cholesterol (ρ = 0.224, P = 0.010), and LDL/HDL ratio (ρ = 0.196, P = 0.026). Moreover, higher total cholesterol (ρ = -0.233, P = 0.010), LDL cholesterol (ρ = -0.235, P = 0.010), and LDL/HDL ratio (ρ = -0.199, P = 0.029) were associated with a stronger decline in HAMD score between study inclusion and direct follow-up. LIMITATIONS: We employed an associational study design, performed only a short-term follow-up, and excluded suicidal study subjects. CONCLUSIONS: Serum lipid levels are associated with depression per se, the depression severity, and the prospective 3-week course. These observations build the basis for future investigations on individualized lipid metabolism-related treatment strategies in depressedpatients.
Authors: Hannah Benedictine Maier; Christoph Pollak; Nicole Moschny; Sermin Toto; Colin Schlatt; Christian K Eberlein; Wolfgang Sperling; Johannes Kornhuber; Kai G Kahl; Stefan Bleich; Alexandra Neyazi; Helge Frieling Journal: J Neural Transm (Vienna) Date: 2022-02-25 Impact factor: 3.850
Authors: Sandra Martín-Peláez; Lluis Serra-Majem; Naomi Cano-Ibáñez; Miguel Ángel Martínez-González; Jordi Salas-Salvadó; Dolores Corella; Camille Lassale; Jose Alfredo Martínez; Ángel M Alonso-Gómez; Julia Wärnberg; Jesús Vioque; Dora Romaguera; José López-Miranda; Ramón Estruch; Francisco J Tinahones; José Lapetra; Fernando Fernández-Aranda; Aurora Bueno-Cavanillas; Josep A Tur; Vicente Martín; Xavier Pintó; Miguel Delgado-Rodríguez; Pilar Matía; Josep Vidal; Clotilde Vázquez; Lidia Daimiel; Emili Ros; Estefanía Toledo; Stephanie K Nishi; Jose V Sorli; Mireia Malcampo; M Ángeles Zulet; Anaí Moreno-Rodríguez; Raquel Cueto-Galán; Diego Vivancos-Aparicio; Antoni Colom; Antonio García-Ríos; Rosa Casas; M Rosa Bernal-López; Jose Manuel Santos-Lozano; Zenaida Vázquez; Carlos Gómez-Martínez; Carolina Ortega-Azorín; Jose Luís Del Val; Itziar Abete; Amaia Goikoetxea-Bahon; Elena Pascual; Nerea Becerra-Tomás; Juan J Chillarón; Almudena Sánchez-Villegas Journal: PLoS One Date: 2022-04-13 Impact factor: 3.240
Authors: C Macchi; C Favero; A Ceresa; L Vigna; D M Conti; A C Pesatori; G Racagni; A Corsini; N Ferri; C R Sirtori; M Buoli; V Bollati; M Ruscica Journal: Cardiovasc Diabetol Date: 2020-11-03 Impact factor: 8.949